期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 63, 期 21, 页码 12359-12386出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c00606
关键词
-
资金
- CSIC [201980E024, 202020E103]
- la Caixa Banking Foundation [HR18-00469]
- Instituto de Salud Carlos III [ISCIII-COV20/01007]
- Spanish Ministry of Science and Innovation [RTI2018-097305-R-I00]
- CONICYT-PCI [REDES190074]
- FONDECYT [11180604]
- H2020-MSCAITN-2017 [765912]
- predoctoral FPU grant [FPU16/04466]
- [FPISGIT2018-04]
Currently, humans are immersed in a pandemic caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health worldwide. To date, no drug or vaccine has been approved to treat the severe disease caused by this coronavirus, COVID-19. In this paper, we will focus on the main virus-based and host-based targets that can guide efforts in medicinal chemistry to discover new drugs for this devastating disease. In principle, all CoV enzymes and proteins involved in viral replication and the control of host cellular machineries are potentially druggable targets in the search for therapeutic options for SARS-CoV-2. This Perspective provides an overview of the main targets from a structural point of view, together with reported therapeutic compounds with activity against SARS-CoV-2 and/or other CoVs. Also, the role of innate immune response to coronavirus infection and the related therapeutic options will be presented.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据